Psychopharmacology  	Psychopharmacology  	 NNP	B-NP
and  	and  	 CC	O
adverse  	adverse  	 JJ	O
effects  	effects  	 NNS	O
of  	of  	 IN	O
antipsychotic  	antipsychotic  	 JJ	B-NP
long-acting  	long-acting  	 JJ	I-NP
injections 	injections 	 NNS	I-NP
:  	:  	 :	O
a  	a  	 DT	O
review  	review  	 NN	B-NP
Depot  	Depot  	 NNP	I-NP
antipsychotics  	antipsychotics  	 NNS	I-NP
are  	are  	 VBP	O
widely  	widely  	 RB	O
used  	used  	 VBN	O
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
practice 	practice 	 NN	I-NP
.  	.  	 .	O
Long-acting  	Long-acting  	 JJ	B-NP
formulations  	formulations  	 NNS	I-NP
of  	of  	 IN	I-NP
second-generation  	second-generation  	 JJ	I-NP
antipsychotics  	antipsychotics  	 NNS	I-NP
are  	are  	 VBP	O
now  	now  	 RB	O
being  	being  	 VBG	O
developed  	developed  	 VBN	O
and  	and  	 CC	O
introduced 	introduced 	 VBD	O
.  	.  	 .	O
To  	To  	 TO	O
review  	review  	 VB	O
the  	the  	 DT	O
pharmacology 	pharmacology 	 NN	O
,  	,  	 ,	O
pharmacokinetics  	pharmacokinetics  	 NN	B-NP
and  	and  	 CC	O
adverse  	adverse  	 JJ	O
effect  	effect  	 NN	B-NP
profiles  	profiles  	 NNS	I-NP
of  	of  	 IN	O
currently  	currently  	 RB	O
available  	available  	 JJ	O
antipsychotic  	antipsychotic  	 JJ	B-NP
long-acting  	long-acting  	 JJ	I-NP
injections  	injections  	 NNS	I-NP
( 	( 	 -LRB-	O
LAIs 	LAIs 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
psychopharmacological  	psychopharmacological  	 JJ	B-NP
properties  	properties  	 NNS	I-NP
of  	of  	 IN	O
first-  	first-  	 JJ	O
and  	and  	 CC	O
second-generation  	second-generation  	 JJ	B-NP
antipsychotic  	antipsychotic  	 JJ	I-NP
LAIs  	LAIs  	 NNS	I-NP
are  	are  	 VBP	O
reviewed  	reviewed  	 VBN	O
using  	using  	 VBG	O
data  	data  	 NNS	O
available  	available  	 VBP	O
up  	up  	 RP	O
to  	to  	 TO	O
October  	October  	 NNP	O
2008 	2008 	 CD	O
.  	.  	 .	O
First-generation  	First-generation  	 JJ	B-NP
antipsychotic  	antipsychotic  	 NNS	I-NP
( 	( 	 -LRB-	O
FGA 	FGA 	 NNP	B-NP
)  	)  	 -RRB-	O
LAIs  	LAIs  	 NNS	B-NP
are  	are  	 VBP	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
high  	high  	 JJ	O
rate  	rate  	 NN	O
of  	of  	 IN	O
acute  	acute  	 JJ	O
and  	and  	 CC	O
chronic  	chronic  	 JJ	B-NP
movement  	movement  	 NN	I-NP
disorders 	disorders 	 NNS	I-NP
.  	.  	 .	O
Risperidone  	Risperidone  	 NNP	B-NP
LAI  	LAI  	 NNP	I-NP
is  	is  	 VBZ	O
better  	better  	 JJR	O
tolerated  	tolerated  	 NN	O
in  	in  	 IN	O
this  	this  	 DT	O
respect 	respect 	 NN	O
,  	,  	 ,	O
but  	but  	 CC	O
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
hyperprolactinaemia  	hyperprolactinaemia  	 NN	B-NP
and  	and  	 CC	O
weight  	weight  	 NN	B-NP
gain 	gain 	 NN	I-NP
.  	.  	 .	O
Olanzapine  	Olanzapine  	 NNP	B-NP
LAI  	LAI  	 NNP	I-NP
causes  	causes  	 VBZ	O
weight  	weight  	 NN	B-NP
gain  	gain  	 NN	I-NP
and  	and  	 CC	O
other  	other  	 JJ	O
metabolic  	metabolic  	 JJ	B-NP
effects  	effects  	 NNS	I-NP
but  	but  	 CC	O
appears  	appears  	 VBZ	O
not  	not  	 RB	O
to  	to  	 TO	O
be  	be  	 VB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
an  	an  	 DT	O
important  	important  	 JJ	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
movement  	movement  	 NN	B-NP
disorders 	disorders 	 NNS	I-NP
.  	.  	 .	O
Dosing  	Dosing  	 NNP	O
of  	of  	 IN	O
LAIs  	LAIs  	 NNP	B-NP
is  	is  	 VBZ	O
complicated  	complicated  	 VBN	O
by  	by  	 IN	O
delayed  	delayed  	 JJ	O
release  	release  	 NN	O
of  	of  	 IN	O
drug 	drug 	 NN	O
,  	,  	 ,	O
changes  	changes  	 NNS	O
in  	in  	 IN	O
plasma  	plasma  	 JJ	B-NP
levels  	levels  	 NNS	I-NP
without  	without  	 IN	O
change  	change  	 NN	O
in  	in  	 IN	O
dose 	dose 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
by  	by  	 IN	O
the  	the  	 DT	O
lack  	lack  	 NN	O
of  	of  	 IN	O
data  	data  	 NNS	O
establishing  	establishing  	 VBG	O
clear  	clear  	 JJ	O
dose  	dose  	 NN	O
requirements 	requirements 	 NNS	O
.  	.  	 .	O
All  	All  	 DT	O
LAIs  	LAIs  	 JJ	B-NP
offer  	offer  	 NN	I-NP
the  	the  	 DT	O
prospect  	prospect  	 NN	O
of  	of  	 IN	O
assured  	assured  	 JJ	O
adherence  	adherence  	 NNS	O
( 	( 	 -LRB-	O
although  	although  	 IN	O
patients  	patients  	 NNS	O
may  	may  	 MD	O
still  	still  	 RB	O
default  	default  	 VB	O
on  	on  	 IN	O
treatment 	treatment 	 NN	O
)  	)  	 -RRB-	O
but  	but  	 CC	O
their  	their  	 PRP$	O
use  	use  	 NN	O
is  	is  	 VBZ	O
complicated  	complicated  	 VBN	O
by  	by  	 IN	O
adverse  	adverse  	 JJ	O
effects 	effects 	 NNS	O
,  	,  	 ,	O
complex  	complex  	 JJ	O
pharmacokinetics  	pharmacokinetics  	 NN	B-NP
and  	and  	 CC	O
confusion  	confusion  	 NN	O
over  	over  	 IN	O
dose-response  	dose-response  	 JJ	B-NP
relationships 	relationships 	 NNS	I-NP
.  	.  	 .	O
